Summary & Overview
HCPCS Q4336: Artacent c per Square Centimeter (Add-on)
HCPCS Level II code Q4336 is an add-on code describing Artacent c billed per square centimeter, used when a biologic graft or tissue product is applied in addition to a primary surgical or wound procedure. Nationally, add-on product codes like Q4336 matter because they affect aggregate surgical episode costs and require correct reporting to ensure clinical documentation aligns with billing. Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn what Q4336 represents, the clinical contexts where it is reported, and the payer landscape typically relevant for coverage and claims processing. The publication provides benchmarks for how add-on biologic product codes are treated by major payers, outlines policy and coverage considerations at a national level, and summarizes clinical usage scenarios tied to operative and wound-care procedures. Data not provided in the input, such as associated taxonomies, ICD-10 diagnoses, and related codes, are noted as unavailable and therefore excluded from detailed tables. This summary is intended to clarify coding intent and the administrative context for providers, billers, and policy analysts handling add-on biologic product reporting.
Billing Code Overview
HCPCS Level II code Q4336 represents Artacent c, billed per square centimeter and is listed as an add-on service to be reported separately in addition to a primary procedure. The service type is a biologic graft or tissue product applied by area, typically used when additional graft material is required beyond a primary wound, surgical, or reconstructive procedure. The typical site of service is an operating room or procedural suite within an inpatient or outpatient surgical setting depending on the primary procedure.
Clinical & Coding Specifications
Clinical Context
A patient with a chronic or acute full-thickness or partial-thickness skin defect following trauma, tumor resection, chronic wound debridement, or burn is evaluated in an outpatient dermatologic surgery clinic or hospital-based wound care unit. The clinician determines that placement of a topical skin substitute, specifically a per-square-centimeter product (Q4336 Artacent C), is appropriate as an adjunct to standard wound management to promote granulation and re-epithelialization. The procedure is performed after wound bed preparation (debridement and hemostasis). The topical product is measured in square centimeters and applied directly to the prepared wound surface; the application is documented with size, number of units, lot numbers, and sterile technique. Typical workflow includes pre-procedure consent, wound measurement and photography, debridement (if required), application of Q4336 per cm2 as an add-on supply item billed in addition to the primary procedure (for example, excision or grafting), post-application dressing, and instructions for follow-up wound checks. Common sites of service are outpatient clinic, ambulatory surgical center, and hospital inpatient wound care areas. Patients often have comorbidities that affect healing such as diabetes, peripheral vascular disease, or immunosuppression, and follow-up visits assess graft/treatment uptake, infection signs, and need for additional products or procedures.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|